Akeso, Inc. ((HK:9926)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Akeso, Inc. is conducting an open-label, multicenter Phase Ib/II clinical study titled An Open Label, Multicenter, Phase Ib/II Clinical Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer. The study aims to evaluate the safety, tolerability, and efficacy of AK130 combined with AK112 in treating advanced biliary tract cancer (BTC), with the goal of determining the recommended phase 2 dose (RP2D) and assessing the efficacy of the combination therapy versus monotherapy.
The interventions being tested are two experimental drugs, AK130 and AK112. AK130 is combined with AK112 to potentially enhance treatment outcomes for patients with advanced BTC.
The study design is interventional, with a randomized allocation and a parallel intervention model. There is no masking involved, and the primary purpose is treatment-focused, aiming to establish the safety and effectiveness of the drug combination.
The study is set to begin on March 10, 2025, with the last update submitted on April 14, 2025. These dates are crucial as they mark the commencement of recruitment and the latest developments in the study’s progress.
This clinical update could influence Akeso’s stock performance positively by showcasing its commitment to advancing cancer treatment options, potentially boosting investor confidence. The study’s progress may also impact the competitive landscape in the oncology sector, particularly among companies focusing on biliary tract cancer therapies.
The study is ongoing, with further details available on the ClinicalTrials portal.